A B S T R A C T The effect of administration of human growth hormone (HGH) (3 mg every 6 hr for 6 days) on the endogenous GH response to insulin-induced hypoglycemia at 8, 12, 24, and 48 hr posttreatment was studied in 11 healthy male adults. Free fatty acid, cortisol, and glucose responses pre-and posttreatment with HGH were evaluated concurrently. Control subjects received saline injections to evaluate relationship of GH responses to the periodicity of insulin tolerance tests. The data were compared for each subject pre-and posttreatment with HGH as well as by comparison of the results of the saline-treated group with those of the HGH-treated group.
INTRODUCTION
Experimental data in rats suggest that growth hormone (GH) may participate in the modulation of its secretion by means of an auto-feedback mechanism operative at the level of the hypothalamus or pituitary gland (2-10); however, evidence for a similar mechanism in man is limited. Women in the third trimester of pregnancy and during the first few weeks postpartum have a reduced GH response to insulin-induced hypoglycemia and to arginine (11) (12) (13) (14) . This behavior is coincident with high circulating levels of human chorionic somatomammotropin (HCS) (15) , a placental hormone which is immunologically and physicochemically similar to GH and exhibits many of its metabolic effects, but at a considerably lower order of potency (16) . The decreased GH response to insulin and arginine provocation observed in late pregnancy and the immediate postpartum period may be a consequence, at least in part, of the high concentration of plasma HCS. Further, we have observed in children that growth hormone release after provocative stimuli may be diminished or absent when the pretest concentration of plasma GH is elevated (17 FIGURE 1 Diagram of the protocol utilized in the study showing the relationships between meals, treatment, and testing procedures.
The present study is an attempt to (a) define GH autoregulation in man by utilizing the GH response to insulin-induced hypoglycemia as a method of assessing this phenomenon, (b) clarify the individual variability in GH response to a hypoglycemic stimulus in a homogeneous population under stringently controlled experimental conditions, and (c) elucidate concurrent changes in the concentration of plasma cortisol and free fatty acid (FFA), substances which have been implicated in the control of GH secretion. The results indicate the presence of GH-induced inhibition of the GH response to insulin-induced hypoglycemia in man.
METHODS
Subjects for this study were 16 male volunteers, aged [24] [25] [26] [27] [28] [29] [30] yr, who were hospitalized for treatment of traumatic orthopedic injury (Table I ), but at the time had convalesced fully. All were ambulatory but restricted to the ward during the study. None had a personal or family history of endocrine or metabolic disease or were obese. None had taken any medication for at least 1 wk before admission to the study.
All studies were carried out on a metabolic ward at a constant temperature (720-740F) in a comfortable, yet stringently controlled, setting in which environmental conditions and subject routine varied little from day to day. The patients were permitted no strenuous exercise and slept only during the night (10 p.m. to 6 a.m.) during which time lights were turned off. Meals were served at standard hours (Fig. 1) ; the diets were isocaloric and contained at least 250 g carbohydrate and approximately 27% fat. All subjects were weighed daily and showed no appreciable weight variation during the course of the study.
Hypoglycemia was induced by intravenous injection of crystalline insulin (ITT) 0.1 U/kg body weight at 8 a.m., 24 hr after admission to the ward. Blood samples were collected from an indwelling venous catheter which was inserted at least 4 hr before ITT (patency of the catheters was maintained by a very slow infusion of normal saline). Samples were collected immediately before injection and 15, 30, 45, 60, 90, and 120. min after insulin administration. A second ITT was done on day 2 to establish base line responses and assess day-to-day variation.
Control period. The subjects were separated into two groups (Table I) on the basis of alternate admission to the study. Group I (n = 5) received normal saline (0.6 cc) intramuscularly every 6 hr for 6 days (days 2-8) and group II (n = 11) received human GH (National Pituitary Agency No. 3-C) dissolved in pyrogen-free water (0.6 cc = 3 mg GH) intramuscularly every 6 hr for 6 days (Fig. 1) . Injection sites were rotated in both groups to avoid excessive local irritation and discomfort. Vials of GH and Plasma glucose in all patients was measured by a glucose oxidase method (18) , plasma GH by a modification of the double antibody method (19) , plasma FFA by a modification of the method of Dole (20) , and plasma corticoids by the competitive protein-binding method (21) . Antibody formation to GH was tested by the method of Berson, Yalow, Bauman, Rothschild, and Newerly (22) . All samples from any individual patient were analyzed during the same assay.
Results were analyzed by nonparametric criteria, which have advantages of (a) independence of the distribution of values from the test population and (b) comparison of data derived from different or independent experimental populations without distortion. The Kruskal-Wallis one-way analysis of variance (23) was used to convert individual scores into ranks, thereby providing high sensitivity as to the direction of the data without introduction of distortion caused by numerical differences (cf. sample calculation, Appendix).
RESULTS
Control period (days 1 Maximal fall in plasma glucose concentration occurred within 30 min of insulin administration in all subjects, on both control days. The variation in maximal hypoglycemic response of individual subjects was minimal (mean difference in lowest plasma glucose concentration between day 1 and 2 was 5.3 ±1.4 mg/100 ml (xj ±SEM, n = 16). The group mean maximal per cent fall in plasma glucose was 62.1 ±2.2% on day 1 and 65.8 ±+1.5% on day 2 (x -+-SEM, n = 16), a negligible variation (Table II) .
GH response. Fasting GH values of 1.0 ng/ml or less were observed on both control days in 13 subjects. 2 subjects (R.Y.A. and Y.E.L.) had a fasting level of 1.2 and 3.2 ng/ml, respectively, on day 1, and a fasting level of 1.0 ng/ml on day 2. Subject R.I.C., whose fasting concentration was 1.0 ng/ml on day 1, had a fasting value of 21.0 ng/ml (on repeated assays) and a 15 min (postinsulin) level of 1.0 ng/ml on day 2. The peak concentration of plasma GH after insulin injection was noted at 60 min in 8 of 16 subjects on day 1 and 9 of 16 subjects on day 2. In P.E.N., peak value was at .120 min on both control tests. In the remaining patients, maximal values occurred at 45 or 90 min. The group mean maximal plasma GH concentration was 31.1 ±3.6 ng/ml (x +SEM, n = 16) on day 1 and 23.4 ±3.1 (n = 16) on day 2, not statistically significant (Table II ). The mean difference in peak plasma GH concentration for an individual subject between day 1 and 2 was 12.1
±2.3 (n = 16). This variation is greater than the ±10%
intra-assay and between-assay variation for the GH radioimmunoassay method utilized in this study. In 4 subjects, the peak values on the two tests fell within 10% of the higher value; 8 of the remaining 12 subjects showed higher peak GH concentrations on day 1. Mild symptoms of hypoglycemia were noted in less than two-thirds of the subjects; when they occurred they conformed temporally to the lowest concentration of plasma glucose. FFA response. 6 subjects had fasting plasma FFA levels > 1000 iAEq/liter on both control days; 2 others had high levels only on day 1, and 2 others only on day 2. The high values were limited to the subjects who were cigarette smokers, as noted by others.' Prohibition of cigarettes was successful only for the 1 FIGURE 2 The height of the bar represents the maximal per cent depression of plasma glucose before and after treatment with saline or GH. Moderate insulin resistance was noted in the GH-treated group at 8 hr as compared with saline-treated group and the control period data. (Table II) .
The results of posttreatment ITT's were compared to the averaged control data for statistical analysis.
When the concentration of plasma GH was measured 3, 5, and 6 hr after an injection of saline, n = 5, or of GH, n = 7, on different days during the postcontrol period, the slope of decrease in the concentration of plasma GH during this slow phase was duplicated closely on different treatment days (Table III) . 40 .
EIJI Posttreatment period (days [8] [9] [10] Glucose response. Fasting plasma glucose levels were comparable in both groups throughout the posttreatment period and were not significantly different from the mean control value. Insulin resistance after GH treatment was noted during the first postinjection ITT (8 hr) (Fig. 2) . The mean maximal per cent fall in the GH-treated group was 34% less than the comparable control value (P < 0.001) and 30.5% less than the mean maximal per cent fall in the saline-treated group (P < 0.02) at 8 hr. The mean maximal per cent fall for the saline-treated group at 12 hr was 23% less than the control value (P < 0.01). Moderate insulin resistance at that time of day (8 p.m.) was anticipated on the basis of a previously described circadian variation in glucose-insulin interrelationships (24) . The mean decrease in plasma glucose at 12 hr was 49.2% in the saline-treated and 47.6% in the GH-treated subjects, suggesting that there was no superimposed GH-induced insulin resistance at that time. The mean maximal per cent decrease in plasma glucose was comparable in both treatment groups at 24 hr (saline group 59.6%, GH group 55.6%) and 48 hr (saline group 63.4%, GH group 62.5%), and was comparable to the control value (Fig. 2) .
In the three GH-treated subjects (W.E.G., W.I.L., and P.E.N.) who were given regular insulin 0.15 U/kg intravenously at 8 hr (a 50% increase in the insulin dose) the mean maximal per cent fall in plasma glucose was 34.7 ±5.8%, n = 3, not significantly different from the per cent fall noted in those GH-treated subjects given only 0.10 U/kg (42.0 ±4.2%). The results (glucose, GH, FFA, and cortisol) obtained in these 3 subjects in all posttreatment ITT's were not included in the statistical data for the GH-treated group, inasmuch as they were given a larger dose of insulin at 8 hr.
GH response. Mean GH were similar (3.0 ±1.1, 3.5 +-0.5 ng/ml) in both treatment groups at 8 hr, and in all succeeding ITT's (Table IV) . Posttreatment results were analyzed in two different ways to minimize artifacts introduced by design of study resulting from biologic variation: data were compared to control data for the same subjects and, alternately, to data for the saline-treated subjects obtained at each test period. When tested at 8 hr the maximal concentration of plasma GH after insulin-induced hypoglycemia (0.1 U/kg) in subjects given GH (4.6 ±1.3 ng/ml) was significantly less than the control value (28.1 ±4.9, P <0.01) (Fig. 3) . A similar suppression in concentration of GH was noted at 12 hr (10.4 ±1.9 ng/ml versus control of 28.1 +-4.9 P < 0.01). The mean maximal concentration at 24 and 48 hr, while 11.1 and 12.0 less than the control value, was not significantly less. Mean maximal concentration was 84% less than that of the saline-treated subjects at 8 hr (P < 0.01) (Fig. 3) . The difference between the mean concentration attained by each group at 12 hr (10.4 versus 36.5 ±5.6 ng/ml) was equally significant (P < 0.01). The mean maximal GH level of the saline-treated subjects at 24 and 48 hr was 3.5 and 9.3 ng/ml less, but not statistically significantly less, than the saline group control value (24.3 +4.2 ng/ ml). The mean peak concentration of the GH-treated subjects at 24 hr (17.0 ±6.5 ng/ml) and 48 hr (16.1 +-2.9 ng/ml) was not significantly different from the value obtained for the saline-treated subjects (20.8 ±5.2 and 15.0 ±2.1 ng/ml, respectively). In the 3 patients who received the higher dose of insulin (0.15 U/kg) at 8 hr., the mean GH values were 4.3 ±0.75 ng/ml (8 hr), 5.6 ±1.6 ng/ml (12 hr), 12 .0 +5.4 ng/ml (24 hr), and 12.5 ±4.7 ng/ml (48 hr). Progressive "recovery" of the GH response to insulin-induced hypoglycemia was observed in many of the GH-treated subjects. The usual course of "recovery" of the GH response is shown for patient H.O.O. (Fig. 4) (Table IV) . The decrease after insulin administration was similar in the GH-treated subjects (55.3 ±4.2%) and the saline-treated subjects (62.0 ±5.1%) at 8 hr (Fig. 5) . The decrease in the GH-treated subjects at 12 hr was similar to that noted for the GH-and saline-treated subjects at 8, 24, and 48 hr. The maximal per cent fall for the saline-treated subjects at 12 hr was 29.1% greater than the control value (P <0.01), the reason for which is obscure. The fall in the GH-treated subjects at 12 hr, while not different from the control value, was significantly less than the unaccountably high value (77.5 ±4.9%) obtained in the saline-treated subject at 12 hr (P < 0.02). The degree of terminal recovery was not different from the control value in any posttreatment period in either treatment group (Fig. 6 ).
Cortisol response. Fasting cortisol values were normal in both treatment groups before and after treatment (Fig. 7) ; diurnal variation was preserved during the period of GH suppression. The rise in plasma cortisol in response to insulin-induced hypoglycemia for the GH-treated subjects was not statistically significantly different from that observed for the saline-treated subjects, before and after the treatment period.
DISCUSSION
This study demonstrates that insulin administration repeated two to three times within 24 hr exerts no significant distortion on the fasting concentration or on the response of plasma glucose to insulin. The magnitude of the GH response to insulin-induced hypoglycemia varied as widely as 30 ng/ml in healthy adult males from day to day despite unchanged study conditions. Comparison of group mean values obtained on different days did not reveal the same variability as the observation of mean individual-subject differences on these days inasmuch as the individual-subject value may change in either a positive or negative direction. The absence of a definite directional trend of this variable GH response with short-interval repetitive insulin administration, suggests that the disparity in daily GH response is a manifestation of intrinsic "biologic variation" and not a consequence of experimental design. The time-course pattern of the GH response was uniformly consistent throughout the series of insulin tolerance tests. A similar individual variation in the FFA response to insulin was encountered. The randomness of the variability makes doubtful a prime distorting influence of repetitive insulin injection.
The maximum GH response of the saline-treated group tended to diminish during the late posttreatment period. The GH response of these subjects at 24 and 48 hr was less than the control or the initial posttreatment responses. A correlation between symptoms of hypoglycemic stress and the magnitude of the rise in plasma The concentration of plasma cortisol (gg/100 ml) before and at 60 min after insulin-induced hypoglycemia, during the control period, and 8
hr and 12 hr after saline or GH administration. The numbers enclosed in the bars refer to the number of subjects is whom cortisol levels were determined. (25) .
The usual GH response to insulin-induced hypoglycemia is absent in subjects who have received 6 days of exogenous GH. This suppression persists many halflives beyond the time at which exogenous GH is contributing significantly to the concentration of plasma GH. The diabetogenic effect of administered GH is apparent 8 hr after the last GH injection. A close correlation of the magnitude of the hypoglycemic stimulus and the rise in plasma GH was suggested by the studies of Frantz and Rabkin (26), but has not been substantiated by subsequent reports (27) (28) (29) . Glick (27) demonstrated that a decrease of 26-39 mg/100 ml in blood glucose after insulin administration leads to a normal GH response. At the 8 hr insulin tolerance test a decrease in blood glucose of 35-40 mg/100 ml was achieved in all the GH-treated subjects. It is doubtful that the diminished release of GH in response to hypoglycemia at the time was due exclusively to a smaller decrease in plasma glucose, since a similar magnitude of glucose depression in saline-treated subjects at 12 hr evoked a substantial GH response. The GH response is significantly inhibited for 12 hr after the completion of GH treatment. Comparison of the GH-treated subjects to themselves as controls indicates that the rise in plasma GH after insulin-induced hypoglycemia is restored to normal in most subjects by 24 hr.
Inhibition of the GH response to a stimulus solely by administration of GH is consistent with the action of a negative "short-loop" feedback mechanism. Autoregulation of adrenocorticotropic hormone (ACTH) was first suggested by the observations of Gemzell and Heijkenskjold (30), Kitay, Holub, and Jailer (31), and Hodges and Vernikos (32) . Characterization of this type of control mechanism for ACTH was described by Motta, Mangili, and Martini in 1965 (33 (40) and, in man, after pituitary stalk section (41, 42) or hypothalamic disease (43, 44) . Also, microinjection of glucose into the hypothalamus, coincident with systemic hypoglycemia, prevents the normal GH response to hypoglycemia (45) . The administration of insulin, therefore, apparently provokes GH secretion by way of a neural arc involving hypothalamic glucoreceptors, and the median eminence as a final common pathway. Further, monkeys with median eminence lesions have normal, detectable fasting levels of plasma GH during inhibition of the GH response to hypoglycemia, just as the human subjects of the present study; this similarity suggests that the pituitary continues tonic function during suppression of a hypothalamic mechanism.
The basic nature of the Gil autofeedback mechanism remains obscure. Irie, Sakuma, Tsushima, Shizume, and Nakao (46) and Muller and Pecile (3) have suggested that modulation of GH secretion is not a function of the polypeptide acting directly on the pituitary gland or hypothalamus, but rather is a result of variation in the concentration of plasma FFA. These findings were not confirmed by Blackard 
